Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Am J Transplant. 2022 Dec;22(12):2931-2941. doi: 10.1111/ajt.17173. Epub 2022 Aug 25.
The heart transplantation policy change (PC) has improved outcomes in high-acuity (Old 1A, New 1-3) patients, but the effect on low-priority (Old 1B/2, New 4-6) patients is unknown. We sought to determine if low-priority patient outcomes were compromised by benefits to high-priority patients by evaluating for interaction between PC and priority status (PS). We included adult first-time heart transplant candidates and recipients from the UNOS registry during a 19-month period before and after the PC. We compared clinical characteristics and performed competing risks and survival analyses stratified by PC and PS. There was a dependence of PC and PS on waitlist death/deterioration with an interaction sub-distribution hazard ratio (adjusted sdHR) of 0.59 (0.45-0.78), p-value < .001. There was a trend toward a benefit of PC on waitlist death/deterioration (adjusted sdHR: 0.86 [0.73-1.01]; p = .07) and an increase in heart transplantation (adjusted sdHR: 1.08 [1.02-1.14], p = .007) for low-priority patients. There was no difference in 1-year post-transplant survival (log-rank p = .22) when stratifying by PC and PS. PC did not negatively affect waitlisted or transplanted low-priority patients. High-priority, post-PC patients had a targeted reduction in waitlist death/deterioration and did not come at the expense of worse post-transplant survival.
心脏移植政策的改变(PC)改善了高危(旧 1A,新 1-3)患者的结局,但对低优先级(旧 1B/2,新 4-6)患者的影响尚不清楚。我们试图通过评估 PC 与优先级状态(PS)之间的相互作用,确定低优先级患者的结局是否因高优先级患者的获益而受到影响。我们纳入了 UNOS 注册中心在 PC 前后 19 个月期间的首次成人心脏移植候选人和受者。我们比较了临床特征,并按 PC 和 PS 进行了竞争风险和生存分析。PC 和 PS 与候补名单上的死亡/恶化有依赖性,交互亚分布危险比(调整后的 sdHR)为 0.59(0.45-0.78),p 值 < .001。PC 对候补名单上的死亡/恶化有获益的趋势(调整后的 sdHR:0.86 [0.73-1.01];p = 0.07),低优先级患者的心脏移植率增加(调整后的 sdHR:1.08 [1.02-1.14],p = 0.007)。按 PC 和 PS 分层时,1 年后移植后的生存率无差异(对数秩检验,p = 0.22)。PC 并没有对等候名单上的或已移植的低优先级患者产生负面影响。高危、PC 后患者的候补名单死亡/恶化率有针对性地降低,而不会导致移植后生存率下降。